PT  - JOURNAL ARTICLE
AU  - Enke, Johanna S.
AU  - Ritzel, Kathrin
AU  - Asbach, Evelyn
AU  - Reitsam, Nic G.
AU  - Märkl, Bruno
AU  - Knösel, Thomas
AU  - Brüdgam, Denise
AU  - Kircher, Malte
AU  - Pfob, Christian H.
AU  - Bundschuh, Ralph A.
AU  - Rinscheid, Andreas
AU  - Nittbaur, Bernd
AU  - Wienand, Georgine
AU  - Schottelius, Margret
AU  - Reincke, Martin
AU  - Lapa, Constantin
AU  - Dierks, Alexander
TI  - C-X-C Motif Chemokine Receptor 4–Directed Scintigraphy Using [<sup>99m</sup>Tc]Tc-Pentixatec in Primary Aldosteronism: A Proof-of-Concept Study
AID  - 10.2967/jnumed.124.268169
DP  - 2024 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1640--1644
VI  - 65
IP  - 10
4099  - http://jnm.snmjournals.org/content/65/10/1640.short
4100  - http://jnm.snmjournals.org/content/65/10/1640.full
SO  - J Nucl Med2024 Oct 01; 65
AB  - C-X-C motif chemokine receptor 4 (CXCR4)–directed imaging has gained clinical interest in aiding clinical diagnostics in primary aldosteronism (PA). We retrospectively evaluated the feasibility of CXCR4-directed scintigraphy using the novel CXCR-4 ligand [99mTc]Tc-pentixatec in patients with PA. Methods: Six patients (mean age ± SD, 49 ± 15 y) underwent CXCR4-directed scintigraphy (including planar imaging and SPECT/CT) 30, 120, and 240 min after injection of 435 ± 50 MBq of [99mTc]Tc-pentixatec. Adrenal CXCR4 expression was analyzed by calculating lesion-to-contralateral ratios (LCRs). Imaging results were correlated to clinical information. Histopathology and clinical follow-up served as the standard of reference. Results: Three subjects showed lateralization of adrenal tracer accumulation, with a mean maximum lesion-to-contralateral ratio of 1.65 (range, 1.52–1.70), which correlated with morphologic findings on CT. One individual underwent adrenalectomy and presented with complete biochemical and clinical remission at follow-up. Histopathologic workup confirmed unilateral aldosterone-producing adenoma. Conclusion: [99mTc]Tc-pentixatec scintigraphy with SPECT in patients with PA is feasible and might offer a valuable alternative to CXCR4-directed imaging with [68Ga]Ga-pentixafor PET.